Predictors of the response to nivolumab immunotherapy in the second or subsequent lines for metastatic non-small cell lung cancers

Checkpoint inhibitors represent the first therapeutic class to replace chemotherapy lines for the treatment of metastatic non-small cell lung cancer (NSCLC), due to improved overall survival and tolerability. Nivolumab, a fully human anti-programmed cell death-1 immunoglobulin G4 monoclonal antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Săftescu, Sorin, Negru, Șerban, Volovăț, Simona, Popovici, Dorel, Chercota, Vlad, Stanca, Simona, Feier, Horea, Malita, Daniel, Dragomir, Radu, Volovăț, Constantin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082661/
https://www.ncbi.nlm.nih.gov/pubmed/33936262
http://dx.doi.org/10.3892/etm.2021.10037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082661/
https://www.ncbi.nlm.nih.gov/pubmed/33936262
http://dx.doi.org/10.3892/etm.2021.10037

Ejemplares similares